Drugs / ALN-XDH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05256810 | Feb 2022 → Jan 2023 | gout | Alnylam Pharmaceuticals | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-20 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout alnylam.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-20 | Alnylam Pharmaceuticals | Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout alnylam.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-XDH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05256810 ↗ |
| Modality | Small interfering RNA (siRNA) | “siRNA” PMID 41388232 ↗ Dec 2025 |
| Route | Subcutaneous | “ALN-XDH administered by SC injection” NCT05256810 ↗ |